Although IL-17 is overexpressed in IBD patients, the IL-17A neutralizing antibody (secukinumab and ixekizumab) and the IL-17A receptor neutralizing antibody (brodalumab) are not effective in CD patients, and some patients have adverse reactions (133–135). This evidence concerns the gene IL17A and Cowden disease.